PET imaging of [
18 kDa translocator protein
Dopamine transporter
PET imaging
Parkinson’s disease
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
18
03
2018
accepted:
07
09
2018
pubmed:
3
10
2018
medline:
8
5
2019
entrez:
2
10
2018
Statut:
ppublish
Résumé
To examine the hypothesis that cerebral binding to the 18 kDa translocator protein (TSPO), a marker of microglia activation, is elevated in Parkinson's disease (PD), and to assess the relationship between brain TSPO binding and dopaminergic pathology in PD. The radioligand [ Based on genotype analysis of the TSPO rs6971 polymorphism, 16 subjects (8 control subjects and 8 PD patients) were identified as high-affinity binders, and the remaining subjects were identified as mixed-affinity binders. A two-way ANOVA showed a strong main effect of TSPO genotype on the cerebral binding of [ The findings do not support the hypothesis of elevated cerebral TSPO binding or a relationship between TSPO binding and dopaminergic pathology in PD.
Identifiants
pubmed: 30270409
doi: 10.1007/s00259-018-4161-6
pii: 10.1007/s00259-018-4161-6
pmc: PMC6333720
doi:
Substances chimiques
(methyl-(11)C)N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine
0
Dopamine Plasma Membrane Transport Proteins
0
Pyrimidines
0
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
367-375Références
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Acta Neuropathol. 2003 Dec;106(6):518-26
pubmed: 14513261
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Mov Disord. 2004 Oct;19(10):1175-82
pubmed: 15390019
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Ann Neurol. 2005 Feb;57(2):168-75
pubmed: 15668962
Neurobiol Dis. 2006 Feb;21(2):404-12
pubmed: 16182554
Neuroimage. 2006 Oct 1;32(4):1690-708
pubmed: 16859930
Mov Disord. 2007 Jan;22(1):41-7
pubmed: 17115387
Prog Neurobiol. 2006 Dec;80(6):308-22
pubmed: 17156911
J Med Chem. 2008 Jan 10;51(1):17-30
pubmed: 18067245
Neuroimage. 2009 May 15;46(1):177-92
pubmed: 19233293
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
Eur J Nucl Med Mol Imaging. 2009 Oct;36(10):1639-50
pubmed: 19437012
Parkinsonism Relat Disord. 2010 Jan;16(1):57-9
pubmed: 19487152
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50
pubmed: 19838702
J Nucl Med. 2011 Jan;52(1):24-32
pubmed: 21149489
J Cereb Blood Flow Metab. 2012 Jan;32(1):1-5
pubmed: 22008728
Mov Disord. 2012 Jan;27(1):8-30
pubmed: 22081500
J Cereb Blood Flow Metab. 2012 Jun;32(6):968-72
pubmed: 22472607
Parkinsonism Relat Disord. 2013 Jan;19(1):47-52
pubmed: 22841687
Anal Bioanal Chem. 2013 Feb;405(4):1303-10
pubmed: 23180082
Neuropsychopharmacology. 2013 May;38(6):938-49
pubmed: 23303049
J Pharm Biomed Anal. 2014 Sep;98:140-3
pubmed: 24922085
J Cereb Blood Flow Metab. 1989 Oct;9(5):696-708
pubmed: 2528555
Science. 2015 Jan 30;347(6221):551-5
pubmed: 25635100
Science. 2015 Jan 30;347(6221):555-8
pubmed: 25635101
J Nucl Med. 2015 May;56(5):701-6
pubmed: 25766898
Brain. 2015 Sep;138(Pt 9):2687-700
pubmed: 26137956
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):173-83
pubmed: 26293827
PLoS One. 2015 Sep 18;10(9):e0138721
pubmed: 26381267
Biochem Soc Trans. 2015 Aug;43(4):586-92
pubmed: 26551697
J Nucl Med. 2016 Feb;57(2):165-8
pubmed: 26697963
Neuroimage. 2016 Jun;133:313-320
pubmed: 26994829
Ann Nucl Med. 2016 Oct;30(8):579-87
pubmed: 27299437
J Neuroinflammation. 2017 Jan 11;14(1):8
pubmed: 28086916
Alzheimer Dis Assoc Disord. 1988;2(4):331-6
pubmed: 2848549
EJNMMI Res. 2017 Dec;7(1):58
pubmed: 28733954
Mov Disord. 2018 Apr;33(4):592-599
pubmed: 29436751
Neurology. 1988 Aug;38(8):1285-91
pubmed: 3399080
Synapse. 1995 Jul;20(3):200-8
pubmed: 7570351
Eur J Nucl Med. 1998 Feb;25(2):173-6
pubmed: 9473266